Acalabrutinib bulk supplier for pharma manufacturers

Acalabrutinib 100 mg Suppliers & Bulk Manufacturers

Available Forms: Oral Capsules

Available Strengths: 100 mg

Reference Brands: Calquence® (EU & US)

Acalabrutinib 100 mg is an oral BTK inhibitor for chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma. It is more selective than the first BTK inhibitor, ibrutinib, with fewer heart-rhythm side effects. The originator product is Calquence by AstraZeneca. Patent status differs by country, so we confirm what can lawfully be supplied to your destination before quoting.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Acalabrutinib? List it or send an offer →

Product Description: Acalabrutinib Capsules are a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By targeting and inhibiting BTK, Acalabrutinib prevents the survival and proliferation of malignant B-cells. Marketed under the brand name Calquence®, Acalabrutinib offers an effective solution for patients who have not responded to other treatments or as a first-line therapy. Available in a 100 mg oral capsule strength, Acalabrutinib is manufactured under GMP-compliant conditions, providing a reliable oncology treatment for US and EU markets.

Acalabrutinib — third party manufacturing & bulk supply

Acalabrutinib 100 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Acalabrutinib is supplied as Oral Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Acalabrutinib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Acalabrutinib →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing